贝达药业（300558）公告，公司于2025年5月8日召开的2024年度股东大会审议通过了《2024年度利润分 配预案》。以总股本4.21亿股为基数，向全体股东每10股派发现金红利1.99元(含税)，共分配现金红利 8369.72万元。股权登记日为2025年6月16日，除权除息日为2025年6月17日。分红派息对象为截止2025 年6月16日在中国证券登记结算有限责任公司深圳分公司登记在册的公司全体股东。公司此次委托中国 结算深圳分公司代派的A股股东现金红利将于2025年6月17日通过股东托管证券公司直接划入其资金账 户。 ...

贝达药业股份有限公司 2024 年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300558 证券简称：贝达药业 公告编号：2025-045 特别提示： 1、贝达药业股份有限公司（以下简称"公司"）于 2025 年 5 月 8 日召开的 2024 年度股东大会审议通过《2024 年度利润分配预案》：以总股本 418,485,885 股为基数，向全体股东每 10 股派发现金红利 2.00 元（含税），共分配现金红利 83,697,177.00 元；剩余未分配利润结转以后年度分配。不进行资本公积金转增股 本，不送红股。若在分配方案实施前公司总股本发生变化的，分配比例将按分派 总额不变的原则相应调整。 二、本次实施的利润分配方案 2、2025 年 5 月 27 日，公司 2023 年限制性股票激励计划首次授予部分第一 个归属期归属股份完成登记并上市流通，本次归属股票 2,247,958 股，归属完成 后公司总股本由 418,485,885 股增加至 420,733,843 股。 3、鉴于在 2024 年度利润分配方案实施前公司总股本发 ...

关注创新药行情全面扩散下的投资机会 证 券 研 究 报 告 2025下半年医药生物行业投资策略 证券分析师：张静含 A0230522080004 2025.6.9 投资案件 一改颓势，医药板块上半年表现亮眼 -15% -10% -5% 0% 5% 10% 15% 20% 25% 2025/01/02 化学制药 生物制品 医疗器械 医药商业 中药 医疗服务 年初至今医药及大盘涨跌幅对比 年初至今医药二级板块涨跌幅对比 -10% -8% -6% -4% -2% 0% 2% 4% 6% 8% 10% 25/01 25/02 25/03 25/04 25/05 25/06 相对全A涨跌幅 医药生物(申万) 万得全A(除金融、石油石化) www.swsresearch.com 证券研究报告 2 ◼ 年初至6/5，医药生物（申万）指数年初至今累计涨跌幅为+8.0%，同期万得全A（除金融石油石化）涨跌幅为 +2.7%，相对大盘涨跌幅为+5.2%，在申万一级行业中排名第5。从二级行业行情表现来看，年初至今涨跌幅排名分 别为：化学制药（35.0x→41.6x）、生物制品（29.8x→41.6x）、医疗器械（30.3x→34.7 ...

Investment Rating - Investment Rating: Positive [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 3.36%, ranking 6th among 31 primary industries, outperforming the CSI 300 index, which decreased by 0.21% [5][17] - The valuation of the pharmaceutical and biotechnology industry as of June 6, 2025, is 28.24x (TTM, excluding negative values), up from 27.60x in the previous period, indicating an upward trend but still below the average [5][23] - Notable sub-industry performance includes chemical preparations and other biological products, with increases of 5.77% and 4.68% respectively, while offline pharmacies saw a decline of 1.15% [5][17] Industry Review - The report highlights three major investment opportunities: 1) Companies with dual-antibody/multi-antibody technology platforms that have differentiated target design capabilities and clinical advancement efficiency are likely to attract international giants [9] 2) Areas with unmet clinical needs, such as advanced liver cancer and non-small cell lung cancer, are promising for dual-antibody therapy development [9] 3) Potential license-out candidates, as domestic innovative pharmaceutical companies continue to engage in global collaborations [9] Important Industry News - CDE launched the "Star Plan" to encourage the development of pediatric anti-cancer drugs, addressing significant unmet clinical needs in this area [7][32] - Alcon's dry eye medication "Tryptyr" received FDA approval, marking it as the first of its kind globally [39] - Hansoh Pharmaceutical's third-generation EGFR-TKI "Amivantamab" was approved in the UK for first-line treatment of NSCLC, becoming the first domestically developed EGFR-TKI approved overseas [42] - BMS and BioNTech entered a collaboration for the dual-antibody candidate BNT327, with an upfront payment of $1.5 billion and potential milestone payments of $7.6 billion [51] Company Dynamics - Stone Pharmaceutical is negotiating three potential deals totaling $5 billion, involving several products including EGFR ADCs [49] - BMS's "Rotecip" was approved for treating lower-risk myelodysplastic syndromes, marking a significant innovation in this therapeutic area [45] - AbbVie’s JAK inhibitor "Upadacitinib" was approved for treating giant cell arteritis, becoming the first approved treatment for this condition in China [48]

Core Insights - The article highlights the performance of the CSI 500 Quality Growth Index, which has shown a positive trend with a 0.35% increase as of June 9, 2025, and mentions specific stocks that have performed well within this index [1] - It emphasizes the outperformance of small-cap stocks this year, driven by improved risk appetite among individual investors, with a focus on identifying high-quality potential "new blue chips" [1] - The report indicates that the quality factor has gained prominence, with the CSI 500 Quality Index outperforming for two consecutive years, while dividend strategies have narrowed, leaving banks as the sole standout [1] Performance Summary - As of May 30, 2025, the top ten weighted stocks in the CSI 500 Quality Growth Index include Chifeng Jilong Gold Mining (600988), Ninebot (689009), and Shenghong Technology (300476), collectively accounting for 23.79% of the index [2] - The performance of individual stocks within the index varies, with notable movements such as Chifeng Jilong Gold Mining decreasing by 2.49% and Ninebot increasing by 1.01% [4] Investment Strategy - The report suggests that investors should focus on stocks with high SIRR (Sustainable Internal Rate of Return) and improving performance in semi-annual reports, particularly within the small-cap segment [1] - It also notes that as economic stability improves, high SIRR stocks in the CSI 300 Quality Growth Index are expected to gradually rise [1]

Group 1: Company Overview - Wuhan Dazhong Dental Medical Co., Ltd. (Dazhong Dental) and Hansi Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. (Hansi Aitai) have recently submitted their listing applications to the Hong Kong Stock Exchange (HKEX) for the second time [1] - Dazhong Dental operates 92 institutions, including 4 hospitals and 80 outpatient departments, covering 8 cities in Hubei and Hunan provinces [2] - Dazhong Dental holds a market share of approximately 2.6% in the private dental service sector in Central China, ranking first among its peers [2] Group 2: Business Segments - Dazhong Dental's main business includes three segments: comprehensive dental treatment services, dental implant services, and orthodontic services, with comprehensive dental treatment accounting for over 50% of total revenue [2] - The company has shown strong customer retention, with a revisit rate increasing from 75.3% in 2022 to 79.6% in 2024 [2] Group 3: Financial Performance - Dazhong Dental's revenue for 2022, 2023, and 2024 was 409 million yuan, 442 million yuan, and 407 million yuan, respectively, while net profit attributable to the parent company was 43.3 million yuan, 50.1 million yuan, and 41.9 million yuan [3] - The company attributed the decline in 2024 performance to consumer downgrade and intensified competition in the dental service industry [3] - The average cost of dental implant services dropped over 30% from 8,460 yuan in 2022 to 5,767 yuan in the first half of 2024 due to national procurement policies [3] Group 4: Investment and Capital Operations - Dazhong Dental previously received investments from institutions such as CITIC Securities and others, but these investors chose to exit before the second listing application in September 2024 [3] - The company repurchased 8.3793 million shares from six investors for 121 million yuan [3] Group 5: Hansi Aitai Overview - Hansi Aitai is an innovative biopharmaceutical company focusing on structural biology, translational medicine, and clinical development, with a core product HX009, a dual-function antibody fusion protein [4] - The company has submitted an updated H-share listing application to HKEX after a previous application expired [4] Group 6: Financial Performance of Hansi Aitai - Hansi Aitai reported losses of 84.623 million yuan in 2023 and 117 million yuan in 2024, primarily due to R&D costs and other operational expenses [5] - R&D costs accounted for 73.0% and 61.8% of total operating expenses in 2023 and 2024, respectively [4][5] Group 7: Investment and Future Outlook for Hansi Aitai - Hansi Aitai has attracted investments from notable institutions and completed a B+ round of financing in June 2024, achieving a post-investment valuation of 1.615 billion yuan [5] - The company has indicated that it will continue to face significant net losses in the foreseeable future and may not achieve or maintain profitability [5]

Core Viewpoint - Hansoh Pharmaceutical's innovative drug, Amivantamab (Aumseqa®), has been approved for marketing in the UK, marking it as the first innovative drug from the company to enter the overseas market and the first Chinese-origin EGFR-TKI to be launched internationally [1][2]. Group 1: Drug Approval and Market Entry - Amivantamab is approved for use as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activated EGFR mutations, as well as for patients with T790M mutation-positive NSCLC [1]. - The drug has already been approved for four indications in China, making it the most approved indication for a Chinese-origin third-generation EGFR-TKI [2]. Group 2: Market Context and Competitors - As of March 2025, there are seven third-generation EGFR-TKI products available in China, including Amivantamab and others like Osimertinib and Furmonertinib [3]. - The market for NSCLC treatments is significant, with lung cancer accounting for 18.7% of global cancer deaths in 2022, and NSCLC being the most common type, representing approximately 85% of all lung cancer cases [4]. Group 3: Historical Context and Future Prospects - The first-generation EGFR-TKI, Gefitinib, was launched in the early 2000s, followed by second-generation drugs that also faced resistance issues, leading to the development of third-generation EGFR-TKIs like Osimertinib [5]. - Current research is focused on addressing resistance issues associated with third-generation EGFR-TKIs, with innovations such as EGFR/C-MET dual antibodies and ADC drugs being explored [6].

[Table_Reportdate] 2025年06月04日 ➢ 1.创新药密集上市，关注后续医保谈判————医药生物行业周报（2025/05/26- 2025/06/01） ➢ 2.供给端扰动背景下，关注相关化工板块配置机会——基础化工行业周报（2025/05/26- 2025/06/01） ➢ 3.白酒持续筑底，重视新消费趋势——食品饮料行业周报（2025/5/26-2025/6/1） ➢ 4.轨交设备板块业绩改善，关注后续铁路固定资产投资进展——机械设备行业周报 （20250526-20250601） 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250604 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的 ...

证券时报·数据宝统计显示，具体到个股，6月3日共有1901只股获融资净买入，净买入金额在千万元以 上的有337只，其中11只融资净买入额超亿元。格力电器融资净买入额居首，当日净买入2.99亿元，其 次是比亚迪、光启技术，融资净买入金额分别为2.76亿元、2.39亿元，融资净买入金额居前的还有美的 集团、五粮液、国电南瑞等。 分行业统计，获融资客净买入超亿元个股中，食品饮料、汽车、家用电器等行业最为集中，分别有2 只、2只、2只个股上榜。板块分布上，大手笔净买入个股中，主板有9只，创业板有2只。 融资客大手笔净买入个股中，从最新融资余额占流通市值比例看，算术平均值为2.87%，融资余额占比 最高的是天阳科技，该股最新融资余额6.61亿元，占流通市值的比例为8.96%，融资余额占比较高的还 有光启技术、赛力斯、比亚迪，占比分别为6.93%、4.34%、3.17%。（数据宝） 6月3日融资客净买入金额排名 截至6月3日，市场融资余额合计1.79万亿元，较前一交易日增加34.52亿元，其中，沪市融资余额 9065.40亿元，较前一交易日增加14.74亿元；深市融资余额8807.56亿元，较前一交易日增加19.81亿元 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant growth in recent months and year-to-date [1]. - As of June 3, 2025, the fund's latest net value is 0.6515 yuan, reflecting a growth of 1.53%. The fund has achieved a return of 6.35% over the past month, 20.21% over the past six months, and 29.38% year-to-date [1]. - The fund's top ten stock holdings account for a total of 56.30%, with notable positions in companies such as Kelun-Botai (9.63%), BeiGene-U (8.84%), and Kangfang Biotech (7.07%) [1]. Group 2 - The Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A was established on August 21, 2020, and as of March 31, 2025, it has a total scale of 1.68 billion yuan [1]. - The fund manager, Zheng Lei, has extensive experience in the finance and healthcare sectors, having held various positions in research and fund management since 2014 [2].